期刊文献+

唑来磷酸联合化疗治疗肺癌骨转移的临床观察 被引量:8

Clinical Observation of Zoledronic Acid Combined with Chemotherapy in Treatment of Bone Metastasis of Lung Cancer
原文传递
导出
摘要 目的观察唑来磷酸联合化疗对肺癌骨转移的止痛效果和不良反应。方法将60例确诊肺癌患者随机分为A、B2组,A组为唑来磷酸联合化疗组,B组单用唑来磷酸组。结果A、B2组止痛有效率分别为86.67%、80.00%。结论唑来磷酸联合化疗治疗肺癌骨转移性疼痛安全有效。 [ Objective] To investigate the antalgic effect and adverse reactions of zoledronic acid combined with chemotherapy in treatment of bone metastasis of lung cancer. [ Methods ] 60 confirmed lung cancer patients were randomly divided into two groups ( group A and group B ). Group A was treated with zoledronic acid combined with chemotherapy, and group B was treated with zoledronic acid alone. [Results]The antalgic effective rate of group A and group B was 86.67% and 80.00%, respectively. [ Conclusion] Zoledronic acid combined with chemotherapy in treatment of bone metastasis of lung cancer is effective and safe.
出处 《职业与健康》 CAS 2009年第21期2350-2351,共2页 Occupation and Health
关键词 肺癌骨转移 联合化疗 唑来磷酸 Bone metastasis of lung cancer combined with chemotherapy Zoledronie acid
  • 相关文献

参考文献8

  • 1Groblewska M, Mroczko B, Czygier M, et al. Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases. Postepy Hig Med Dosw ( Online), 2008,62:668 - 675.
  • 2Kim S, Takahashi H, Lin WW, et al. Carcinoma - produced factors ac- tivate myeloid cells through TLR2 to stimulate metastasis. Nature, 2009,457 : 102 - 106.
  • 3Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab, 2009, 22:55 - 63.
  • 4Mantovani A. Cancer : Inflaming metastasis. Nature, 2009, 457 (7225) :36 - 37.
  • 5Bertoldo F, Tonini G, Vincenzi B, et al. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. Nat Rev Clin Oncol, 2009,6 : 191 - 192.
  • 6Okamoto K, Tsurutani J, Terashima M, et al. Zoledronie acid-induced regression of multiple metastases at nonskeletal sites. Ann Oncol, 2009, 20:796 - 797.
  • 7Smith A, Kressley A, Saif MW. Oral osteonecrosis associated with the use ofzoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOE, 2009,10:212 - 214.
  • 8McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics, 2008,26:251 - 268.

同被引文献49

  • 1王颖超,张洁霞,谭获,欧阳铭.唑来膦酸治疗非小细胞肺癌骨转移的临床研究[J].现代医院,2007,7(3):23-25. 被引量:2
  • 2Rosen LS, Gordor D, Kaminskim, et al. Long- term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeleted complications in patients with advanced multiple myeloma or breast carcinoma: a randomized double blind, multicenter[ J ]. Comparative trail Cancer,2003, 98 (3) : 1735 - 1744.
  • 3Clezard IN P. The antitumor potential of bisphosphonates [ J ]. Serain Oncol,2002,29 ( Suppl 21 ) :33 -42.
  • 4Foum Ier P, Bo Isser S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone stimulated vascular regrowth in the ventral prostate in castrated rats[ J]. Cancer Res,2002,62 (22) :6538 -6544.
  • 5Thomas JP,Vladimir M.Zoledronic acid in the management of metastatic bone disease[J].Ther Clin Risk Manag,2008,4(2):261-268.
  • 6Berenson JR. Zoledronic acid in cancer patients with bone metastase: results of Phase Ⅰ and Ⅱ trals [ J ]. Semin 0ncol,2011,28 (2Suppl 6) :25-34.
  • 7Cheer SM. Zoledronic acid [ J ]. Drugs,2011,61 (6) : 799-805.
  • 8Polascik TJ,Mouraviev V. Zoledronic acid in the man-agement of metastatic bone disease[J].Ther Clin Risk Manag,2008,(01):261-268.
  • 9Singh N,Aggarwal AN. Quality of life as an end-point of treatment efficacy in malignant lung tumours[J].{H}LANCET ONCOLOGY,2008,(09):820-821.
  • 10Lipton A,Small E,Saad F. The new bisphospho-nate,Zometa(zoledronic acid),decreases skeletal compli-cations in both osteolytic and osteoblastic lesions:a com-parison to pamidronate[J].{H}CANCER INVESTIGATION,2002,(z2):45-54.

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部